Trend Review: American Express Company (NYSE:AXP), Kitov Pharmaceuticals Holdings Ltd (ADR) (NASDAQ:KTOV)
Trading the news is a technique to trade equities, currencies and other financial instruments on the financial markets. Trading news releases can be a noteworthy tool for financial shareholders. Economic news reports often drive strong short-term moves in the markets, which may create trading opportunities for traders. Declarations about corporate profits, a change in administration, rumors of a merger, are events that can cause a company’s share price to move wildly up or down. Interest rates, unemployment and export rates, or the central bank’s policy shifts, can cause a deep change of an exchange rate.
Shares of American Express Company (NYSE:AXP) gained 0.35% to $85.52 on Tuesday. The stock settled at $85.52 per share, after floating in a range of $84.76 to $85.56. The stock moved on low volume, traded at a volume of 2.81 shares, as compared to its average daily volume of 3.34M shares. The market capitalization for the company is reported at $76.38B. Trading volume, or volume, is the number of shares or contracts that point towards the overall activity of a security or market for a given period. Trading volume is a key technical indicator an investor uses to identify momentum in a stock and confirm a trend or trend reversal. Volume gives an investor an idea of the price action of a security and whether he should buy or sell the security.
Trading volume can also signal when an investor should take profits and sell a security because of low activity. If there is no relationship between the trading volume and the price of a security, this signals weakness in the current trend and a possible reversal.
Kitov Pharmaceuticals Holdings Ltd (ADR) (NASDAQ:KTOV) opened at $1.49. It reached an intraday trading high of $1.79 and closed at $1.47. Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV) (KTOV), an innovative biopharmaceutical company, recently declared results of a pre-clinical study demonstrating that NT-219, the lead drug candidate of its partner TyrNovo Ltd., in combination with Keytruda®, converted non-responding tumors to responders and blocked tumor progression in an immune-oncology preclinical model.
The study, conducted in partnership with researchers at Bar Ilan University and Rabin Medical Center, assessed NT-219’s ability to overcome cancer drug resistance in a patient-derived xenograft (PDX) model of immune-deficient mice, in which a tumor originated from an esophagus cancer biopsy was implanted. The mice were supplemented with immune cells from the same patient (double autologous). While no response was observed with Keytruda® alone or with NT-219 alone, and the tumors aggressively progressed, mice treated concomitantly with a combination of Keytruda® and NT-219 demonstrated complete blockage of tumor progression.
“We are excited with these initial results obtained with NT-219 in combination with pembrolizumab (Keytruda®),” stated Dr. J. Paul Waymack, Chairman of Kitov’s Board and Chief Medical Officer. “Previous results obtained with NT-219 demonstrated its efficacy in overcoming drug resistance in various cancers and in combination with various pharmacologic cancer therapies. We are focused on advancing this highly promising therapeutic candidate to clinical trials as quickly as possible in order to provide improved treatment options to cancer patients.”
The stock price inclined 0.12 points or 8.89% at the market. The total volume traded for the day is 2.12M higher as compared to its average daily volume of 247,890 shares. The current EPS for the company has been recorded at $-0.11 and the beta value recorded by the company stands at 0.00 points.